alexa Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
Anesthesiology

Anesthesiology

Journal of Anesthesia & Clinical Research

Author(s): Key NS, Nelsestuen GL

Abstract Share this page

Abstract The development of recombinant factor VIIa (rFVIIa) has greatly augmented the range of treatment options available for hemophilia patients with inhibitors. However, there still remains a lack of consensus regarding several aspects of treatment with bypassing agents such as rFVIIa, prothrombin complex concentrates (PCC), and activated PCC (aPCC). Such unresolved issues may be clarified by the identification of a suitable laboratory monitoring method with which to correlate clinical outcomes. This paper will review the need for an effective and informative monitoring strategy, and will discuss several candidate methods that have been employed for the measurement of hemostatic efficacy following therapy with bypassing agents. To date, however, no assay endpoint has been developed that can correlate accurately with clinical outcomes in a sufficiently large patient sample.
This article was published in Semin Hematol and referenced in Journal of Anesthesia & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords